Extending Indication for Islet Autotransplantation in Pancreatic Surgery (AutoTx)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2012 by Ospedale San Raffaele
Information provided by (Responsible Party):
Piemonti Lorenzo, Scientific Institute San Raffaele
ClinicalTrials.gov Identifier:
First received: October 3, 2012
Last updated: March 4, 2015
Last verified: October 2012
Islet autotransplantation (IAT) is a therapeutic approach used to prevent pancreatogenic diabetes or to reduce the severity of diabetes after a major pancreatectomy. Total pancreatectomy with IAT is being used almost exclusively for treatment of chronic pancreatitis. More recently, indications other than chronic pancreatitis have been reported including IAT after extended pancreatectomy performed for the resection of benign tumors of the mid-segment of the pancreas or IAT after total pancreatectomy for severe abdominal trauma In this study, we study our experience with IAT for the treatment of a broader population of patients undergoing pancreatic surgery including subjects with technically unfeasible or high risk pancreatic anastomosis during partial pancreatectomy and subjects undergoing completion pancreatectomy because of anastomosis leakage after pancreatoduodenectomy for nonmalignant or malignant diseases.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Autologous Pancreatic Islet Cell Transplantation for Improved Glycaemic Control After Pancreatectomy: Observational Study

Further study details as provided by Ospedale San Raffaele:

Primary Outcome Measures:
  • Beta cell function [ Time Frame: month 1, 3, 6, 12 and every year up to death ] [ Designated as safety issue: No ]
    Beta-cell function will be assessed by fasting C peptide, HbA1c,glycaemia, change in average daily insulin requirements, basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the arginine test, beta-score and Transplant Estimated Function

Secondary Outcome Measures:
  • Incidence of complications after pancreatic surgery [ Time Frame: 90 days from discharge ] [ Designated as safety issue: Yes ]
    Complications will be defined and graded according to the Novel Grading System classification ( DeOliveira et al 2006). A special emphasis is given to life-threatening and permanently disabling complications.

Other Outcome Measures:
  • Incidence of each individual postoperative complication [ Time Frame: 90 days from discharge ] [ Designated as safety issue: Yes ]
    1. death
    2. pancreatic fistula defined according to the International Study Group on Pancreatic Fistula (Bassi C et al 2005)
    3. delayed gastric emptying (DGE) defined according to the International Study Group on Pancreatic Fistula (Wente et al 2007)
    4. intra-abdominal complications
    5. medical complications

Biospecimen Retention:   Samples With DNA
Serum, PBMC

Estimated Enrollment: 150
Study Start Date: February 2012
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)
patients with chronic pancreatitis treated with total or subtotal pancreatectomy
patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who underwent partial or total pancreatectomy

Inclusion Criteria:

  • 18 years of age

    • ability to provide written informed consent
    • fasting glycaemia <126 mg/dl without glucose-lowering medications.

Exclusion Criteria:

  • Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial
  • Diagnosis of intraductal papillary mucinous cancer, unless the absence of multifocal lesion is demonstrated by endoscopic US
  • Presence of multifocal or residual disease at the pancreatic margin. If a malignat disease is the reason for the surgery, 1 cm of the pancreatic remnant in proximity to the pancreatic margin will be resected and sent for immediate pathologic analysis to confirm margin negativity and to rule out multifocal tumor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01702051

Contact: Gianpaolo Balzano, MD 0226432664 ext 0039 balzano.gianpaolo@hsr.it
Contact: Paola Maffi, MD 0226462575 ext 0039 maffi.paola@hsr.it

Ospedale San Raffaele (OSR) Recruiting
Milan, Italy, 20132
Contact: Gianpaolo Balzano, MD    0226432664 ext 0039    balzano.gianpaolo@hsr.it   
Principal Investigator: Lorenzo Piemonti, MD         
Principal Investigator: Gianpaolo Balzano, MD         
Principal Investigator: Paola Maffi, MD         
Sponsors and Collaborators
Ospedale San Raffaele
Principal Investigator: Lorenzo Piemonti, MD Scientific Institute San Raffaele
Study Director: Gianpaolo Balzano, MD Scientific Institute San Raffaele
  More Information

Responsible Party: Piemonti Lorenzo, Director Islet Transplantation Program, Scientific Institute San Raffaele
ClinicalTrials.gov Identifier: NCT01702051     History of Changes
Other Study ID Numbers: 43-09/02/2012 
Study First Received: October 3, 2012
Last Updated: March 4, 2015
Health Authority: Italy: Ministry of Health

Keywords provided by Ospedale San Raffaele:
Pancreatogenic diabetes
Autologou Islet Transplantation

ClinicalTrials.gov processed this record on May 26, 2016